Crescita Therapeutics Inc.
CTX.TO
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 87.11% | -11.80% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 87.11% | -11.80% | |||
| Cost of Revenue | 133.98% | -11.91% | |||
| Gross Profit | 48.35% | -11.70% | |||
| SG&A Expenses | -4.57% | -4.74% | |||
| Depreciation & Amortization | 13.94% | 2.97% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 43.99% | -6.83% | |||
| Operating Income | 88.28% | -12.62% | |||
| Income Before Tax | 83.45% | -12.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 84.77% | -12.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 84.77% | -12.25% | |||
| EBIT | 88.28% | -12.62% | |||
| EBITDA | 110.71% | -16.59% | |||
| EPS Basic | 84.52% | -13.22% | |||
| Normalized Basic EPS | 84.96% | -12.84% | |||
| EPS Diluted | 84.52% | -7.95% | |||
| Normalized Diluted EPS | 84.96% | -12.84% | |||
| Average Basic Shares Outstanding | -0.78% | -0.88% | |||
| Average Diluted Shares Outstanding | -0.78% | -0.88% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||